Md Omar Faruqe

Mr. Md Omar Faruqe

University of Rajshahi, Rājshāhi, Bangladesh
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
Alomgir HossainAlomgir Hossain
Alomgir Hossain
EREkhtiar Rahman
Ekhtiar Rahman
SRSiddiqur Rahman
Siddiqur Rahman
KNKhondokar Nasirujjaman
Khondokar Nasirujjaman
Mohammad Nurul MatinMohammad Nurul Matin
Mohammad Nurul Matin
Muhammad Fazle RabbeeMuhammad Fazle Rabbee
Muhammad Fazle Rabbee

21 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MIMd. Ariful Islam
Md. Ariful Islam
MHMd. Bayazid Hossen
Md. Bayazid Hossen
AHAbu Horaira
Abu Horaira
AHAlim Hossen
Alim Hossen
MKMd Kaderi Kibria
Md Kaderi Kibria
MMMd. Nurul Haque Mollah
Md. Nurul Haque Mollah
Colorectal cancer (CRC) is one of the most common cancers with a high mortality rate. Early diagnosis and therapies for CRC may reduce the mortality rate. However, so far, no researchers have yet investigated core genes (CGs) rigorously for early diagnosis, prognosis, and therapies of CRC. Therefore, an attempt was made in this study to explore CRC-related CGs for early diagnosis, prognosis, and therapies. At first, we identified 252 common differentially expressed genes (cDEGs) between CRC and control samples based on three gene-expression datasets. Then, we identified ten cDEGs (AURKA, TOP2A, CDK1, PTTG1, CDKN3, CDC20, MAD2L1, CKS2, MELK, and TPX2) as the CGs, highlighting their mechanisms in CRC progression. The enrichment analysis of CGs with GO terms and KEGG pathways revealed some crucial biological processes, molecular functions, and signaling pathways that are associated with CRC progression. The survival probability curves and box-plot analyses with the expressions of CGs in different stages of CRC indicated their strong prognostic performance from the earlier stage of the disease. Then, we detected CGs-guided seven candidate drugs (Manzamine A, Cardidigin, Staurosporine, Sitosterol, Benzo[a]pyrene, Nocardiopsis sp., and Riccardin D) by molecular docking. Finally, the binding stability of four top-ranked complexes (TPX2 vs. Manzamine A, CDC20 vs. Cardidigin, MELK vs. Staurosporine, and CDK1 vs. Riccardin D) was investigated by using 100 ns molecular dynamics simulation studies, and their stable performance was observed. Therefore, the output of this study may play a vital role in developing a proper treatment plan at the earlier stages of CRC.

27 May 2024 in Molecules
Verified
Journal Article
Open access
PDF file
MAMd. Ahad Ali
Md. Ahad Ali
HSHumaira Sheikh
Humaira Sheikh
Muhammad YaseenMuhammad Yaseen
Muhammad Yaseen
Md Omar FaruqeMd Omar Faruqe
Md Omar Faruqe
IUIhsan Ullah
Ihsan Ullah
MMMd. Nurul Haque Mollah
Md. Nurul Haque Mollah
The outbreak of SARS-CoV-2, also known as the COVID-19 pandemic, is still a critical risk factor for both human life and the global economy. Although, several promising therapies have been introduced in the literature to inhibit SARS-CoV-2, most of them are synthetic drugs that may have some adverse effects on the human body. Therefore, the main objective of this study was to carry out an in-silico investigation into the medicinal properties of Petiveria alliacea L. (P. alliacea L.)-mediated phytocompounds for the treatment of SARS-CoV-2 infections since phytochemicals have fewer adverse effects compared to synthetic drugs. To explore potential phytocompounds from P. alliacea L. as candidate drug molecules, we selected the infection-causing main protease (Mpro) of SARS-CoV-2 as the receptor protein. The molecular docking analysis of these receptor proteins with the different phytocompounds of P. alliacea L. was performed using AutoDock Vina. Then, we selected the three top-ranked phytocompounds (myricitrin, engeletin, and astilbin) as the candidate drug molecules based on their highest binding affinity scores of −8.9, −8.7 and −8.3 (Kcal/mol), respectively. Then, a 100 ns molecular dynamics (MD) simulation study was performed for their complexes with Mpro using YASARA software, computed RMSD, RMSF, PCA, DCCM, MM/PBSA, and free energy landscape (FEL), and found their almost stable binding performance. In addition, biological activity, ADME/T, DFT, and drug-likeness analyses exhibited the suitable pharmacokinetics properties of the selected phytocompounds. Therefore, the results of this study might be a useful resource for formulating a safe treatment plan for SARS-CoV-2 infections after experimental validation in wet-lab and clinical trials.

6 December 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
MHMd. Bayazid Hossen
Md. Bayazid Hossen
AIAriful Islam
Ariful Islam
SRSelim Reza
Selim Reza
KKKaderi Kibria
Kaderi Kibria
AHAbu Horaira
Abu Horaira
MMMd. Nurul Haque Mollah
Md. Nurul Haque Mollah

1 April 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Alomgir HossainAlomgir Hossain
Alomgir Hossain
EREkhtiar Rahman
Ekhtiar Rahman
Md Omar FaruqeMd Omar Faruqe
Md Omar Faruqe
ASAhmed Saif
Ahmed Saif
SSSuzzada Suhi
Suzzada Suhi
Kwang-Hyun BaekKwang-Hyun Baek
Kwang-Hyun Baek
Diabetes, characterized by elevated blood sugar levels, poses significant health and economic risks, correlating with complications like cardiovascular disease, kidney failure, and blindness. Dipeptidyl peptidase-4 (DPP-4), also referred to as T-cell activation antigen CD26 (EC 3.4.14.5.), plays a crucial role in glucose metabolism and immune function. Inhibiting DPP-4 was anticipated as a potential new therapy for diabetes. Therefore, identification of plant-based natural inhibitors of DPP-4 would help in eradicating diabetes worldwide. Here, for the identification of the potential natural inhibitors of DPP-4, we developed a phytochemicals library consisting of over 6000 phytochemicals detected in 81 medicinal plants that exhibited anti-diabetic potency. The library has been docked against the target proteins, where isorhamnetin, Benzyl 5-Amino-5-deoxy-2,3-O-isopropyl-alpha-D-mannofuranoside (DTXSID90724586), and 5-Oxo-7-[4-(trifluoromethyl) phenyl]-4H,6H,7H-[1,2]thiazolo[4,5-b]pyridine 3-carboxylic acid (CHEMBL3446108) showed binding affinities of −8.5, −8.3, and −8.3 kcal/mol, respectively. These compounds exhibiting strong interactions with DPP-4 active sites (Glu205, Glu206, Tyr547, Trp629, Ser630, Tyr662, His740) were identified. ADME/T and bioactivity predictions affirmed their pharmacological safety. Density functional theory calculations assessed stability and reactivity, while molecular dynamics simulations demonstrated persistent stability. Analyzing parameters like RMSD, RG, RMSF, SASA, H-bonds, MM-PBSA, and FEL confirmed stable protein–ligand compound formation. Principal component analysis provided structural variation insights. Our findings suggest that those compounds might be possible candidates for developing novel inhibitors targeting DPP-4 for treating diabetes.

28 May 2023 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
MHMd. Eram Hosen
Md. Eram Hosen
SRSojiur Rahman
Sojiur Rahman
Md Omar FaruqeMd Omar Faruqe
Md Omar Faruqe
KHKhalekuzzaman
Khalekuzzaman
MIMd. Asadul Islam
Md. Asadul Islam
Rashed ZamanRashed Zaman
Rashed Zaman